Table 4.
Comparative summarized data of patients from the so far largest published case studies for PG between 1985 to 2011[1-3,18,19]
| Powell et al. (1985) | von den Driesch (1997) | Bennett et al. (2000) | Al Ghazal et al. (2011) | Binus et al. (2011) | Our data | |
|---|---|---|---|---|---|---|
| Patients |
86 |
44 |
86 |
49 |
103 |
259 |
| Sex (m:w) |
1:1 |
1:2.1 |
1:1.3 |
1:1.5 |
1:3.1 |
1:1.2 |
| Age (mean) |
7-71 yrs. |
11-80 yrs. |
2-83 yrs. |
22-95 yrs. |
22-88 yrs. |
21-94 yrs. |
| (n.r.) |
(50.3 yrs.) |
(48.4 yrs.) |
(59.7 yrs.) |
(51.6 yrs.) |
(57.3 yrs.) |
|
| Pathogenesis - trauma/surgery |
23 (27%) |
17 (39%) |
n.r. |
16 (33%) |
32 (31.1%) |
111 (42.8%) |
|
Inflammatory disorders | ||||||
| Arthrosis, non rheumatoid arthritis |
28 (33%) |
n.r. |
10 (12%) |
1 (2%) |
20 (19.4%) |
17 (6.6%) |
| Rheumatoid arthritis |
n.r. |
5 (11%) |
n.r. |
3 (6%) |
10 (9.7%) |
24 (9.3%) |
| chronic inflammatory bowel disease |
31 (36%) |
6 (14%) |
18 (21%) |
3 (6%) |
35 (34%) |
24 (9.3%) |
| Crohn: 14 (16%) |
Crohn: 3 (7%) |
Crohn: 8 (9%) |
Crohn: 1 (2%) |
Crohn: 17 (16.5%) |
Crohn: 7 (2.7%) |
|
| Ulcerat. col.: 17 (20%) |
Ulcerat. col.: 3 (7%) |
Ulcerat. col.: 10 (12%) |
Ulcerat. col.: 2 (4%) |
Ulcerat. col: 18 (17.5%) |
Ulcerat. col.: 17 (6.6%) |
|
|
Endocrine disorders | ||||||
| Thyreoid disease |
5 (6%) |
n.r. |
n.r. |
7 (14%) |
4 (3.9%) |
29 (11.2%) |
| Diabetes mellitus |
2 (2%) |
n.r. |
n.r. |
14 (29%) |
29 (28.2%) |
66 (25.5%) |
| Neoplasia | ||||||
| |
16 (19%) solid: 5 (6%) |
5 (11%) solid: 1 (2%) |
8 (9%) solid: n.r. |
16 (33%) solid: 6 (12%) |
21 (20.4%) solid: n.r. |
32 (12.4%) solid: 22 (8.5%) |
| hematolog.: 11 (13%) |
hematolog.: 4 (9%) |
hematolog.: 8 (9%) |
hematolog: 5 (10%) |
hematolog.: 21 (20.4%) |
hematolog.: 10 (3.9%) |
|
| solid neoplasms |
Bladder: 1 (1%) |
Glioblastoma mult.: 1 (2%) |
n.r. |
Breast: 2 (4%) |
n.r. |
Breast: 6 (2.3%) |
| Colon: 2 (2%) |
|
|
Prostate: 1 (2%) |
|
Lung: 3 (1.2%) |
|
| Prostate: 1 (1%) |
|
|
Melanoma: 2 (4%) |
|
Prostate: 3 (1.2%) |
|
| |
|
|
Glioblastoma mult.: 1 (2%) |
|
Melanoma: 3 (1.2%) |
|
| |
|
Liver: 2 (0.8%) |
||||
| |
|
Ovary: 2 (0.8%) |
||||
| |
|
Colon: 1 (0.4%) |
||||
| |
|
Larynx: 1 (0.4%) |
||||
| |
|
Glioblastoma mult.: 1 (0.4%) |
||||
|
Haematological/haematopoetic neoplasia | ||||||
| AML |
1 (1%) |
n.r. |
n.r. |
0 |
1 (0.97%) |
1 (0.4%) |
| CLL |
n.r. |
1 (2%) |
n.r. |
0 |
n.r. |
0 |
| CML |
n.r. |
1 (2%) |
n.r. |
2 (4%) |
n.r. |
2 (0.8%) |
| Other | ||||||
| Myelodysplasia |
n.r. |
n.r. |
3 (4%) |
0 |
2 (1.9%) |
0 |
| Polycythemia rubra vera |
1 (1%) |
n.r. |
n.r. |
0 |
2 (1.9%) |
0 |
| Monoclonal gammopathy |
9 (10%) |
n.r. |
4 (5%) |
2 (4%) |
10 (9.7%) |
3 (1.2%) |
| Plasmocytoma |
n.r. |
1 (2%) |
|
0 |
1 (1.0%) |
2 (0.8%) |
| POEMS syndrome |
n.r. |
n.r. |
1 (1%) |
0 |
n.r. |
0 |
| Mycosis fungoides/ cutaneous T-cell lymphoma |
n.r. |
1 (2%) |
n.r. |
1 (2%) |
n.r. |
2 (0.8%) |
| Hodgkin’s lymphoma |
n.r. |
n.r. |
n.r. |
0 |
1 (1.0%) |
0 |
| Myelofibrosis |
n.r. |
n.r. |
n.r. |
0 |
1 (1.0%) |
0 |
| Large granular lymphocytic leukaemia |
n.r. |
n.r. |
n.r. |
0 |
1 (1.0%) |
0 |
| other Non-Hodgkin’s lymphoma | n.r. | n.r. | n.r. | 0 | 1 (1.0%) | 0 |
n. r. = not reported.